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Open access uBackground and purpose: Carbonic anhydrase (CA) IX expression is increased upon hypoxia and has been
proposed as a therapeutic target since it has been associated with poor prognosis, tumor progression and
pH regulation. The aim of this study was to evaluate the antitumor activity of a high CAIX-afﬁnity indane-
sulfonamide (11c) combined with irradiation, compared with the general CA inhibitor acetazolamide
(AZA).
Material and methods: HT-29 carcinoma cells with or without (genetic knockdown, KD) CAIX expression
were incubated with 11c/AZA under different oxygen levels and proliferation, apoptosis and radiosensi-
tivity were evaluated. 11c/AZA was administered intravenously (1/day; 5 days) to tumor-bearing mice
and tumor irradiation (10 Gy) was performed at day 3 of the injection period. Tumor growth and poten-
tial treatment toxicity were monitored (3/week).
Results: Treatment with 11c/AZA alone resulted in tumor regression, which was further increased in CAIX
expressing cells by combining 11c with irradiation. AZA demonstrated also an additional effect in the KD
tumors when combined with irradiation. CAIX inhibition in vitro signiﬁcantly reduced proliferation and
increased apoptosis upon hypoxia exposure without affecting intrinsic radiosensitivity.
Conclusions: Speciﬁc inhibition of CAIX activity enhanced the effect of tumor irradiation and might,
therefore, be an attractive strategy to improve overall cancer treatment.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
Radiotherapy and Oncology 99 (2011) 424–431High tumoral carbonic anhydrase (CA) IX expression has been
associated with poor prognosis, tumor progression and aggressive-
ness [1,2]. CAIX is a dimeric glycoprotein, contains an HRE element
essential for its transcriptional activation upon hypoxia by HIF-1a
and regulates tumor pH by catalyzing the reversible hydration of
carbon dioxide to bicarbonate and a proton [2,3]. Since the active
site of CAIX resides in the extracellular space, it contributes to
the acidiﬁcation of the extracellular environment during hypoxia
[4]. Furthermore, it has been shown that CAIX plays an important
role in maintaining a neutral intracellular pH within tumors. The
bicarbonate ion resulting from the CAIX catalyzed reaction can
be imported into the cytoplasm by exchange with a chloride anion
to serve as substrate for intracellular carbonic anhydrases such as
CAII in order to neutralize intracellular protons [5]. Since CAIX isn Oncology (MAASTRO Lab),
iology, Maastricht University
aastricht, The Netherlands.
ity.nl (L. Dubois).
nder the Elsevier OA license.implicated in both extra – and intracellular pH regulation, it has
been proposed as a potential therapeutic target.
A possible approach to target CAIX would be via inhibiting its
enzymatic activity with speciﬁc pharmacological inhibitors [6].
Previously, we have demonstrated that binding of sulfonamides
to CAIX requires both its expression and its activation and this oc-
curs only during hypoxia [7]. Also in animal models, sulfonamide
accumulation was proven to be dependent on the tumor oxygena-
tion [8]. Administration of membrane-impermeable derivatives of
acetazolamide, a general carbonic anhydrase inhibitor, resulted
in tumor growth inhibition [9]. Aromatic sulfonamides were able
to reduce tumor cell proliferation and intracellular pH, accompa-
nied with an increase in ceramide-mediated apoptotis [10]. Re-
cently, treatment of mammary tumor-bearing mice with novel
CAIX-speciﬁc (ureido)-sulfonamide and glycosylcoumarins inhibi-
tors resulted in a signiﬁcant inhibition of tumor growth and metas-
tasis formation [1].
These reports emphasize that CAIX-speciﬁc sulfonamides are
promising to pursue for their tumor-speciﬁc therapeutic properties
with irradiation. The aim of this study was to explore in genetic
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high afﬁnity for CAIX, compared with the general clinically ap-
proved CA inhibitor acetazolamide (AZA). First we investigated
the binding property of a ﬂuorescent labeled sulfamate (FC11) to
validate the genetic models. Furthermore, we hypothesize that
speciﬁc inhibition of CAIX activity only targets CAIX under hypoxia
resulting in decreased tumor cell proliferation, induction of apop-
tosis and an enhanced effect of irradiation in vivo in a CAIX depen-
dent manner.
Material and methods
Cell culture and model
Exponentially growing colorectal (HT-29, ATCC HTB-38) carci-
noma cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum. To knockdown CA9,
the HuSH-29 shRNA targeting CA9 (TR314250) and empty vector
(R20003) were purchased from Origene. Cell lines were transfected
using FuGENE 6 (Roche, Germany) according to the manufacturer’s
instructions. Cells were then grown under selective pressure
(300 ng/ml puromycin) until no mock-transfected cells remained.
Two individual clones were selected using cloning cylinders (Sig-
ma) and maintained under selection. Data of the independent
clone KD2 are presented in Supplementary Fig. 1. Low oxygen con-
ditions were acquired in a MACS VA500 micro-aerophilic worksta-
tion (Don Whitley Scientiﬁc, Shipley, UK). The atmosphere in the
chamber consisted of 0.2% (hypoxia) or <0.02% (anoxia, 0%) O2,
5% CO2 nd residual N2 [11]. In parallel, normoxic (20% O2) dishes
were incubated in air with 5% CO2.Inhibition CAIX activity
The ﬂuorescent labeled sulfamate (FC11) directed against CAIX
has been prepared by reaction of sulfamyl chloride with the resi-
due obtained from the reaction of ﬂuorescein isothiocyanate (FITC)
with 4-aminophenol (see Supplementary data). 11c was synthe-
sized as previously described [12] and acetazolamide (AZA) was
obtained from Sigma. The structure and Ki value of the different
compounds are depicted in Fig. 1A. Compounds were dissolved in
culture medium containing 1% DMSO at a ﬁnal concentration of
100 lM just before addition to the cells. For the animal experi-
ments, 11c and AZA were dissolved in NaCl 0.9% containing 1%
DMSO to a ﬁnal concentration of 45 mg/kg and injected intrave-
nously via a lateral tail vein.Immunoblotting and quantitative real-time PCR
Experiments were performed as previously described [8,13].
Antibodies used were M75 (kindly provided by Silvia Pastorekova,
Institute of Virology, Slovak Academy of Science, Bratislava, Slovak
Republic) against CAIX or b-actin (Cell Signaling) as loading con-
trol. CAIX (F-CATCCTAGCCCTGGTTTTTGG, R-GCTCACACCCCCTT
TGGTT) and VEGF (F- GACTCCGGCGGAAGCAT, R- TCCGGGCTC
GGTGATTTA) gene abundance was detected with power SYBR
Green I (Applied Biosystems) and normalized to the expression
levels of 18S RNA.FACS analysis
Cells were incubated with FC11 30 min before ﬁxation in freshly
prepared 2% paraformaldehyde. Apoptosis was detected using
Alexa Fluor 488 annexin V (Molecular Probes) and propidium
iodide (PI; Sigma) according to the manufacturer’s guidelines.
Fluorescence was analyzed using ﬂow cytometry (FacsSort, BD Bio-
sciences) with FITC and TRITC settings and data were normalizedto the signal intensity of normoxic exposed cells. Apoptotic cells
were scored as annexin V positive and PI negative.Immunoﬂuorescence
Cells were grown in culture slides (BD Biosciences), incubated
with FC11, ﬁxed with 2% paraformaldehyde and ﬂuorescence was
visualized using a Zeiss Axioskop. Cells for apoptosis staining were
permeabilized using 0.2% Triton X-100 (Sigma). Non-speciﬁc bind-
ing was blocked using 5% normal goat serum (RT, 2 h). Cells were
incubated (4 C, ON) with cleaved Caspase-3 monoclonal antibody
(Cell Signaling) followed by incubation (RT, 2 h) goat anti-rabbit
Alexa Fluor 488 conjugate. Before mounting with Shandon Immu-
nomount (Thermo Fisher), cells were incubated with DAPI (rt,
10 min).CA activity assay
Carbonic anhydrase activity was determined as described previ-
ously [14]. Cells were washed with cold isotonic HBS buffer and
incubated (20 min) with sulfonamide. pH was monitored over time
before and after addition of cold CO2 saturated solution.Lactic acid assay
Lactic acid concentration in the culture medium of cells exposed
to sulfonamide treatment was determined using the Lactic Acid kit
(Biosentec) following the manufacturer’s instructions.Animal experiments
Cells were resuspended in Basement Membrane Matrix (Matri-
gelTM BD Biosciences) and injected subcutaneously into the lateral
ﬂank of adult NMRI-nu (nu/nu) mice (28–32 g). Animals were trea-
ted with sulfonamides at a tumor volume of 165 ± 58 mm3 for
5 days (45 mg/kg daily) and irradiated with a single dose (10 Gy,
[15]) in the middle of the treatment. Tumor growth was monitored
until reaching 4 the volume at irradiation time and treatment
toxicity was scored by body weight measurements. Animal facili-
ties and experiments were in accordance with local institutional
guidelines for animal welfare and were approved by the Animal
Ethical Committee of the University.Cell growth
Cells were seeded at 5000 cells/well in 24-well plates and ex-
posed for normoxia or hypoxia for 1–3 days. After incubation, cells
were ﬁxed with 4% paraformaldehyde (10 min) and stained with
0.1% Crystal violet solution (30 min). Extraction was done with
10% acetic acid (15 min) and absorbance at 590 nm was measured
(FLUOstar Omega).Clonogenic survival
Cells were exposed to normoxia or anoxia for 24 h, subse-
quently irradiated (N: 2, 4, 6 and 8 Gy; A: 4, 8, 12 and 16 Gy;
225 kV Philips X-ray tube), trypsinized and plated in triplicate for
clonogenic survival. Cells were allowed to form colonies during
14 days which were ﬁxed and stained with 4% methylene blue in
70% ethanol. Afterward, colonies were counted in an automated
way (Oxford Optronix).Statistics
All statistical analyseswere performedwithGraphPadPrismver-
sion 5.01 for Windows (GraphPad Software, 2007, California, USA).
Fig. 1. (A) Chemical structure and afﬁnity (Ki) for CAI, CAII and CAIX of the investigated CA inhibitors. (B) CAIX and VEGF mRNA expression under different oxygen
concentrations (%) relative to normoxia for HT-29 parental, EV and KD1 cells. (C) Western blot analysis of CAIX expression in normoxic (N), hypoxic (H) or reoxygenated (R:
0.2% O2, 24 h followed by 1 h 20% O2) conditions for the different cell lines. b-Actin was used as the loading control. (D) Representative ﬂuorescence analysis of cells treated
with 100 lM FC11 under the respective oxygen conditions. (E) Quantitative FACS analysis of FC11 binding relative to normoxia. Data represent the mean ± SD of at least three
independent experiments. Asterisk indicates signiﬁcant difference (⁄P < 0.05, ⁄⁄P < 0.01). Data for an independent CAIX KD (KD2) are shown in Supplementary Fig. 1.
426 CAIX inhibition and radiotherapyAn unpaired student’s t-test and non-parametric Mann–Whitney U
test for small groups were used to determine the statistical signiﬁ-cance of differences between two independent groups of variables.
For all tests, a P < 0.05 was considered signiﬁcant.
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HT-29 colorectal carcinoma cells showed elevated CA9 mRNA
and CAIX protein levels in response to reduced oxygen concentra-
tions, which remained high upon reoxygenation (Fig. 1B and C). To
investigate the role of CAIX in extracellular acidosis and to facili-
tate the establishment of a causal relationship between CAIX
expression and its therapeutic effect in more detail, CA9 was si-
lenced genetically in a constitutive manner. A signiﬁcant reduction
in CA9 mRNA levels was observed for the KD cell line at 0.2% (hy-
poxia; P = 0.002) and 0% (anoxia; P = 0.029) O2 as compared with a
scrambled control (EV) cell line, which demonstrated similar
expression levels as the HT-29 parental cell line. Additionally, CAIX
protein levels were abolished in the KD cells (Fig. 1C). Furthermore,
other HIF responsive genes were not affected as demonstrated byFig. 2. (A) Extracellular rate of acidiﬁcation and (B) medium lactic acid concentrations of
AZA or vehicle (DMSO). Data represent the mean ± SD of at least four independent experthe increased VEGF expression levels upon reduced oxygen concen-
trations for both cell lines (Fig. 1B).
To deﬁne the oxygen conditions required for inhibitor binding,
accumulation of the ﬂuorescent sulfamate FC11 with high afﬁnity
for CAIX (Ki = 12 nM) was investigated. Signiﬁcant higher
(P = 0.009) FC11 binding was observed at HT-29 and EV cells ex-
posed to hypoxia (0.2%) as compared with their normoxic counter-
parts (Fig. 1D and E), corresponding with elevated CAIX expression.
Binding was dramatically reduced (P = 0.002) compared with hyp-
oxic conditions when FC11 was added upon reoxygenation,
although CAIX expression levels remained high. No FC11 accumu-
lation was observed at KD cells, corresponding with the absence of
CAIX expression.
Next we examined whether CAIX depletion resulted in a
decreased capacity to acidify the extracellular environment uponcells exposed to normoxia (N) or hypoxia (H) after pre-treatment with 100 lM 11c,
iments. Data for an independent CAIX KD (KD2) are shown in Supplementary Fig. 1.
428 CAIX inhibition and radiotherapyhypoxia. The faster rate of acidiﬁcation upon hypoxia was abol-
ished in the KD cells relative to the HT-29 parental and EV cells
(Fig. 2A top). To deﬁne the necessity for CAIX activity for extracel-
lular acidiﬁcation in hypoxic conditions, the effect of a speciﬁc
CAIX (11c) and a general CA (AZA) sulfonamide inhibitor on hypox-
ia-induced changes in extracellular pH was tested in these cells.
The hypoxic acidiﬁcation rate could be inhibited by the addition
of 11c to HT-29 and EV cells, while no effect was seen in the KD
cells (Fig. 2A middle). The effect of AZA was even more pro-
nounced, resulting in an acidiﬁcation rate lower than seen under
normoxic conditions (Fig. 2A bottom) and was also observed for
the KD cells, indicating the lack of speciﬁcity of AZA for CAIX. Pro-
duction of lactic acid was signiﬁcantly higher upon hypoxia and no
differences could be observed in cultures of CAIX-positive and
CAIX-negative cells or upon CAIX activity inhibition (Fig. 2B), indi-
cating that the lower hypoxic rate of acidiﬁcation upon CAIX activ-
ity inhibition was not caused by interfering with the lactic acid
production pathway.
To investigate in this exploratory study the consequences of
CAIX activity inhibition on tumor growth and radiotherapy re-
sponse, HT-29 tumors were established and mice were treated
with 11c at a volume of 165 mm3 for 5 days and irradiated with
a single dose (10 Gy) at the middle of the treatment. 11c treatment
resulted in a signiﬁcant slower tumor growth (P = 0.024) compared
to vehicle controls. An increased speciﬁc doubling time was ob-
served when treated with irradiation as a single treatment, which
was further increased (P = 0.016) by combining 11c with irradia-
tion (Fig. 3A top). To exclude non-speciﬁc activity of 11c, experi-
ments were repeated in the EV and KD models. A ﬁrst
observation was that the KD tumors grew slower compared with
the EV tumors, indicating the importance of CAIX expression for
tumor progression. Therefore, animals were treated with sulfona-
mides at a similar volume for both the EV and the KD tumors. No
effect of 11c (P = 0.530) and no enhanced tumor effect upon com-
bination treatment (P = 0.724) were observed relative to the vehi-
cle control and irradiation alone, respectively, for the KD tumors as
compared with the EV tumor model (Fig. 3A bottom), demonstrat-
ing the CAIX speciﬁcity of 11c treatment. Next, we examined if the
clinically approved general CA inhibitor AZA exerted similar effects
on therapy response. AZA treatment resulted in an increased spe-
ciﬁc doubling time only in the EV group (P = 0.009). Although no
effect was found for the KD tumors (P = 0.202), AZA demonstrated
additional effects on both groups when combined with irradiation
(Fig. 3B), conﬁrming its broader spectrum of action. Additionally,
none of the treatment schedules caused any observable toxicity
as monitored by body weight loss (data not shown).
To exclude that CA inhibition has an effect on intrinsic radiosen-
sitivity, the response of the EV and KD cells to a combination of sul-
fonamides and a range of radiation doses in vitro was measured
under normoxia and anoxia (Fig. 4A). Both cell lines demonstrated
a more radioresistant phenotype under anoxic conditions. How-
ever, incubation with 11c or AZA before irradiation did not result
in enhancement of the irradiation effect. Therefore, the increased
growth delay could not be explained by changes in radiosensitivity.
Next we investigated whether inhibition of CAIX activity could
affect proliferation and apoptosis as possible explanation for the
in vivo enhanced effect when combining irradiation and sulfona-
mides. In general, proliferation was higher for the EV and KD cells
compared with the HT-29 parental cell line. Under normoxic con-
ditions, neither 11c nor AZA inhibited tumor cell proliferation
(Fig. 4B). Although cell growth decreased for all cell lines under
hypoxic conditions, proliferation was more reduced by 11c and
AZA administration only in CAIX expressing cells. However, the
antiproliferative capacity of AZA was lower than that of 11c. In
the KD cells, the sulfonamides could not decrease cell proliferation
(Fig 4B). AZA and more efﬁciently, 11c signiﬁcantly induced earlyapoptotic events in HT-29 parental and EV cells under hypoxia as
monitored by cleaved caspase-3 ﬂuorescence (Fig. 4C), while no ef-
fect was found for the KD cells. Flow cytometry detection of annex-
in V showed an increased hypoxia to normoxia apoptotic ratio for
11c and to a lesser extent for AZA only in HT-29 and EV cells
(Fig. 4D), conﬁrming our ﬁndings on caspase-3 activation.Discussion
CAIX has been associated with tumorigenic transformation, tu-
mor cell migration and invasion through its capacity to acidify the
extracellular microenvironment of hypoxic tumors [16] and is,
therefore, a potential therapeutic target. Recently, sulfonamide-
based CAIX inhibitors have been proposed as potential antitumor
agents [6]. Accumulation of a novel ﬂuorescent labeled sulfamate
FC11 (Ki = 12 nM) correlated with CAIX expression in HT-29 and
EV cells exposed to hypoxia. Although CAIX expression levels re-
mained high upon reoxygenation in these cells, in agreement with
the known half-life of 38 h [17], sulfamate accumulation was
markedly reduced. Additionally, no accumulation was observed
in CAIX KD cells. Previously, we obtained similar results with a
ﬂuorescent labeled sulfonamide [7,8] and together these data indi-
cate that sulfonamides only accumulate on CAIX expressing cells
during hypoxia.
Hypoxia is known to cause an acidiﬁcation of the extracellular
environment and it has been reported that CAIX is the main con-
tributor for this process [4,14]. We obtained similar data showing
that CAIX depletion slows the faster acidiﬁcation rate under hy-
poxia. Furthermore, acetazolamide and indanesulfonamide 11c
were also able to prevent extracellular acidiﬁcation only during hy-
poxia in a CAIX-dependent manner, with a more CAIX-speciﬁc ef-
fect for 11c compared to the general CA inhibitor acetazolamide,
in agreement with previous reports [14]. It has been reported that
lactic acid production is increased upon hypoxia and could predict
treatment outcome by its possible contribution to the tumor acid-
iﬁcation [18]. Our data indicate that CAIX inhibition had no inﬂu-
ence on lactic acid production either under normoxia or hypoxia.
Similar results were obtained upon elimination of the CAIX cata-
lytic active domain [4], indicating that the extracellular acidity
upon hypoxia better is explained by CAIX activation than by lactic
acid production.
Recently, it has been demonstrated that the tumor response to
fractionated irradiation is determined by the amount of extracellu-
lar acid production [18,19]. Since CAIX-speciﬁc sulfonamides coun-
teract extracellular acidiﬁcation, we hypothesize that these
compounds are able to sensitize tumor to irradiation. First, we ob-
served that CAIX silencing resulted in slower tumor growth rela-
tive to the scrambled controls. Previous reports from breast and
colorectal xenograft models conﬁrmed the requirement of hypox-
ia-induced CAIX expression in the regulation of tumor growth
[1,20]. Single treatment with CAIX-speciﬁc sulfonamide 11c or
general CAIX inhibitor acetazolamide resulted in a signiﬁcant
slower tumor growth compared to vehicle controls in a CAIX-
dependent manner. Similar results were obtained using CAIX-spe-
ciﬁc (ureido)-sulfonamides and glycosylcoumarins or membrane-
impermeable derivatives of acetazolamide in mammary or colorec-
tal tumor-bearing mice [1,9]. Irradiation as a single treatment in-
creased the speciﬁc doubling time independent of CAIX
expression. Previously, we have demonstrated that a single dose
of 10 Gy is sufﬁcient to induce a growth delay in colorectal xeno-
grafts [21]. This is the ﬁrst report showing that CAIX-speciﬁc sul-
fonamides could increase the effect of irradiation in a CAIX
dependent manner, since an effect was observed only for the
HT-29 parental and EV groups, while no enhancement was ob-
served for the KD tumors, demonstrating CAIX speciﬁcity of the
Fig. 3. 11c (A) or AZA (B) was administered when tumors reached an average size of 165 mm3 (45 mg/kg, 5 days) and tumors were irradiated (10 Gy) at day 3 (set to 0) of this
carbonic anhydrase activity inhibitor (CAI) treatment. Tumor growth was monitored until reaching 4 the volume at irradiation time and speciﬁc doubling time was
calculated. Data represent the mean ± SD of four to eight independent animals and asterisks indicate statistical signiﬁcance (⁄P < 0.01; ⁄⁄P < 0.001), NS = not signiﬁcant.
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upon sulfonamide treatment might explain this increased response
to irradiation. In contrast, AZA demonstrated an additional effect inboth groups when combined with irradiation, which could be
explained by the additional inhibition of the intracellular CAII. Re-
cently, it has been shown that CAII is critical for pH homeostasis in
Fig. 4. (A) Clonogenic survival assay after exposure to different doses of irradiation upon normoxia (Norm: 0, 2, 4, 6 and 8 Gy) and anoxia (Anox: 0, 4, 8, 12 and 16 Gy)
exposed cells after pre-treatment with 100 lM 11c or AZA. (B) Cell proliferation of cells exposed to 100 lM 11c or AZA was monitored under normoxic (N) or hypoxic (H)
conditions by Crystal Violet staining after 1–3 days of growth. (C) Representative images of cleaved Caspase-3 staining (green) of normoxic (Norm) or hypoxic (Hyp) cells
exposed to 100 lM 11c or AZA. Nuclear counterstaining is assessed with DAPI (blue). (D) Quantitative FACS analysis of the hypoxia to normoxia (Hyp/Norm) apoptotic ratio,
as assessed by Alexa Fluor annexin V ﬂuorescence. Data represent the mean ± SD of three independent experiments. Asterisk indicates signiﬁcant difference (⁄P < 0.05). Data
for an independent CAIX KD (KD2) are shown in Supplementary Fig. 1.
430 CAIX inhibition and radiotherapyGI-tract organs [22] and, therefore, treatment of these tissue-re-
lated tumors warrants precautions for additional toxicity.
We also examined the possible molecular mechanisms underly-
ing this antitumor effect of CAIX inhibition. The increased growth
delay of the combination treatment could not be explained bychanges in intrinsic radiosensitivity, since the compoundshadnoef-
fect on survival of cells exposed in vitro to a range of radiation doses.
The current exploratory study suggests that the enhanced effect of
sulfonamide treatment combined with irradiation is the result of
changes in the tumormicroenvironmentwhich renders itmore sen-
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activity using sulfonamides also decreased cell proliferation and in-
duced apoptosis only upon hypoxia and could, therefore, induce a
signiﬁcant antitumor effect, in agreement with previous reports
[10]. Maintaining a neutral intracellular pH is a key cellular strategy
to protect tumor cells against apoptotic death and to permit tumor
cell proliferation. Our data suggest that the potential antitumor effect
of CAIX inhibition may be linked to intracellular acidosis and the
underlyingmolecular mechanisms are currently under investigation.
Furthermore, the decreased cell proliferation and induced apoptosis
were more efﬁcient when inhibition is selective suggesting that the
antitumor effect of CA inhibitors is mainly mediated by inhibition of
CAIX. Furthermore, it has been shown that general CA inhibitionusing
AZA can inhibit the invasive capacity of cells and this effect is attrib-
uted to inhibition of the CAII and CAXII isoforms, since only a low re-
sponse was observed for CAIX-positive cells [23].
To exclude that the therapeutic effect of the combination of sul-
fonamide and irradiation results from normal tissue effects, it is
necessary to investigate radiation-induced damage on intestinal
(short-term toxicity) and lung (long-term toxicity) epithelium
and to calculate the dose modifying factors (DMF) for both tumor
and normal tissues. Recently, experts of an ESTRO committee aim-
ing at writing guidelines for the development of targeted drugs
associated with radiation, concluded that such normal tissue
experiments are needed before new agents are tested with radio-
therapy in a clinical setting (D. Hollywood, personal communica-
tion) [24]. We expect to ﬁnd only an increased DMF for the
tumor, since no signs for normal tissue toxicity were observed in
the current study. Furthermore, we are currently designing stable
carcinoma cells which can be induced to down-regulate gene
expression in order to closely mimic the clinical situation, since tu-
mors should be established with a wild type genotype and subse-
quently the CAIX gene can be switched off, allowing to investigate
the effect of CAIX down-regulation.
In conclusion, our experiments demonstrate that speciﬁc inhibi-
tion of CAIX activity only targets CAIX under hypoxia resulting in a
decreased hypoxic rate of extracellular acidiﬁcation and tumor cell
proliferation and induction of apoptosis without affecting the
intrinsic radiosensitivity. In vivo, a therapeutic enhancement was
observed only in CAIX expressing tumors when combined with
irradiation, indicating a causal relationship between CAIX expres-
sion and its therapeutic effect. Furthermore, our data indicate the
potential utility of CAIX inhibition as a new strategy for tumor-spe-
ciﬁc targeting to eventually improve the response to irradiation
treatment.
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